Pioneering Botanical Therapies for Inflammatory and Neurological Diseases
Investor Summary | 2024
Pioneers in Botanical Therapeutics
Founded in 2021, Canurta Therapeutics develops botanically derived therapies for inflammatory and neurological diseases. Focused on rare polyphenols like cannflavins, we aim to deliver safe, effective treatments for conditions like ALS. Our lead candidate, CNR-401, leverages cutting-edge research and patented technologies, redefining neurodegenerative care.
Innovating Neurodegenerative Care with Nature
Harnessing Nature's Rarest Polyphenols
Cannflavins A (CFA) & B (CFB) are rare cannabis-derived polyphenols with potent anti-inflammatory and neuroprotective effects. Preclinical studies show they’re 30 times more effective and safer than Aspirin, targeting key proinflammatory enzymes (mPGES-1, 5-LO) and regulating neuroprotective enzymes like MAGL and FAAH. These compounds offer a groundbreaking approach to treating chronic inflammation and neurodegeneration.
Milestones and Growth
Neurodegenerative Complexity
By 2050, the number of people living with neurodegenerative diseases is expected to increase by nearly 60%.
Lead Candidate CNR-401
CNR-401 optimizes cannabinoids with CFA and terpenoids to alleviate symptoms, enhance quality of life, and provide neuroprotection in ALS and related neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia.
CBD
Other Minor Cannabinoids
Terpenoids
CFA
Innovative Composition: A synergistic blend of CBD, CFA, and terpenoids enhances multi-target efficacy.
​
Safety Profile: Minimal side effects and low-risk dosing, supported by Sativex, a cannabinoid-based drug approved in 30+ countries for ALS symptoms.
​
Lipid-Based Formulation: Designed for peak bioavailability and easy oral administration.
​
Scalable & Sustainable: GMP-compliant and utilizes upcycled plant materials.
​
Regulatory Alignment: FDA rescheduling, the 2018 Farm Bill, and Botanical Drug Guidance offer a clear path, while global cannabis programs expand access.
Mechanisms of Action
CNR-401's unique formulation targets key processes like inflammation, neuroprotection, and muscle control, offering therapeutic benefits across multiple pathways to address the complex mechanisms of diseases like ALS.
Vast Market Potential
The neurodegenerative disease market is rapidly expanding, providing a prime opportunity for CNR-401 to drive innovation. Consistent growth and rising prevelance fuel strong investment prospects.
​
$969M ALS Market: Projected by 2028.
​
Orphan Designation Exclusivity: 7 years in the US and 10 in the EU, granting market dominance.
​
Only Two FDA-Approved Botanical Drugs: Highlighting an untapped market.
​
Pipeline-in-a-product: Potential for blockbuster status across multiple conditions.
Current Treatment Limitations
Go-to-Market Strategy
Revenue Projections
Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands. Profitability is reached in 2027, and by 2028, revenue grows to $231.1M, with ongoing expansion into key global markets.
We are raising $5M in our Pre-Seed round
Early investors gain a first-mover advantage in the rapidly growing neurodegenerative market, supported by proprietary cannabis therapies and de-risked through government-backed funding.
​
First-in-Human Study: Utilizing early data to drive success in the Registration Trial.
​
Early Market Entry: Launching in Germany’s medical cannabis program to gather real-world evidence.
​
CMC and Facility Completion: Advancing CMC work and completing a state-of-the-art facility to scale production and fuel growth.
​
Public Listing: Targeting a 2025 TSV-X public listing.
Mapping the Journey to Botanical Drug Approval
Investigator Initiated Trials (2026)
Early-stage clinical data gathered from IITs, supporting therapeutic potential and accelerating regulatory submissions.
Registration Trial (2028)
Large-scale trials begin, leading to conditional approval under fast-track approval, setting the stage for global regulatory submissions and market entry.
Initial Market Entry (2025)
Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands.
Orphan Drug Designation (2027)
ODD approval solidifies market exclusivity and fast-tracks CNR-401's path to ALS treatment.
Phase IV Confirmatory Trials (2030)
Co-developed confirmatory trials enable broader global market access under the 505(b)(2) pathway, leading to full product approval and widespread use.
Lucrative Exit Potential
Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands. Profitability is reached in 2027, and by 2028, revenue grows to $231.1M, with ongoing expansion into key global markets.
Exit
11.3B
(2030 +/- 3 years)
7.2B (2021)
Potential ROI at Exit | |
---|---|
Average Return | 90.16x |
PIPE 3 | 12.2x (916.6M) |
PIPE 2 | 48.9x (1.46B) |
PIPE 1 | 195.56x (997M) |
RTO Warrants | 176x ($667M) |
Pre-Seed Equity | 189.8x (949M) |
Partnered for Success
Canurta expands its offerings, reaches new markets, and taps into specialized expertise through collaborations with innovative partners across industry, academia, and government.